SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-323741
Filing Date
2021-11-09
Accepted
2021-11-09 07:09:58
Documents
13
Period of Report
2021-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d257443d8k.htm   iXBRL 8-K 25598
2 EX-99.1 d257443dex991.htm EX-99.1 49899
  Complete submission text file 0001193125-21-323741.txt   210000

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA scph-20211109.xsd EX-101.SCH 2918
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE scph-20211109_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scph-20211109_pre.xml EX-101.PRE 11877
6 EXTRACTED XBRL INSTANCE DOCUMENT d257443d8k_htm.xml XML 3467
Mailing Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803
Business Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

IRS No.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38293 | Film No.: 211389843
SIC: 2834 Pharmaceutical Preparations